IDEXX Laboratories Reports 14.3% Revenue Growth to $1.14 Billion in Q1 2026

IDEXX Laboratories, Inc. reported a significant increase in financial performance for the first quarter of 2026, with total revenue reaching $1.14 billion, a 14.3% increase from $998.4 million in the same period last year. The growth was driven by a 14.6% rise in revenue from the Companion Animal Group (CAG) segment, which accounted for $1.05 billion, bolstered by higher volumes and increased prices in IDEXX VetLab consumables and reference laboratory services. The company also saw service revenue rise to $474.7 million, up from $425.4 million, contributing to a net income of $278.4 million, compared to $242.7 million in the prior year.

In terms of operational metrics, IDEXX's gross profit margin improved to 63.4%, up from 62.4% in the previous year, reflecting operational productivity improvements and net price realization. The company reported a 100 basis point increase in gross profit margin, despite inflationary pressures. Operating expenses rose to $360.2 million, up from $306.8 million, primarily due to increased personnel-related costs and a significant impairment charge related to an equity investment. The company’s effective tax rate remained stable at 21.7%.

IDEXX's balance sheet showed total assets of $3.39 billion as of March 31, 2026, compared to $3.35 billion at the end of 2025. Cash and cash equivalents increased to $200.5 million from $180.1 million, while total liabilities rose to $1.83 billion, up from $1.75 billion. The company’s working capital decreased to $154.2 million, attributed to higher borrowings under its credit facility, which stood at $530 million, up from $398 million at the end of 2025.

Strategically, IDEXX has continued to expand its product offerings and customer base, with notable growth in its veterinary software and diagnostic imaging systems. The company reported a 12% increase in its installed base of premium instruments, which has supported higher testing volumes. Additionally, IDEXX has been actively repurchasing shares, with $360.8 million spent on stock buybacks during the quarter, reflecting its commitment to returning value to shareholders.

Looking ahead, IDEXX anticipates continued revenue growth driven by strong demand in its core segments, despite potential challenges from macroeconomic factors such as inflation and currency fluctuations. The company expects to leverage its robust product pipeline and customer retention strategies to sustain its growth trajectory, with a focus on maintaining operational efficiency and enhancing its market position in the veterinary diagnostics sector.